A leader in specialty pharmaceutical innovation
Welcome to Paladin Labs
With headquarters in Montréal, Canada, Paladin Labs Inc. is a leading specialty pharmaceutical company focused on acquiring or licensing emerging pharmaceuticals for the Canadian market.
Their dedicated sales and marketing organization has propelled Paladin to become one of Canada’s pioneers in specialty pharmaceuticals.
Paladin is an operating company of Endo International plc (NASDAQ: ENDP), a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients through excellence in development, manufacturing and commercialization.
An innovative specialty pharmaceutical company
Press Releases
17-Jan-2022
Paladin Labs Inc. Announces the Launch of Xydalba® (dalbavancin for injection) in Canada
09-Jun-2021
Paladin Labs Inc. Announces Approval of Wakix® (pitolisant) in Canada
05-Jan-2021
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada
31-Jul-2019
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
22-Feb-2019
Paladin Labs Inc. Announces Approval of Envarsus PATM (tacrolimus prolonged-release tablets) in Canada
25-Jul-2018
Bioprojet and Endo Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Pitolisant in Canada
10-Jun-2015
ARIAD and Paladin Announce Commercial Distribution Agreement for Iclusig (Ponatinib) in Canada
9- Feb- 2015
Paladin Labs Announces the Canadian Launch of Zincofax® Spray
19-Aug-2013
Paladin Labs Announces the Canadian Launch of Emtrix®
For complete list of press releases click Here.